Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -73.55% | 173.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.17% | 41.89% | |||
| Operating Income | 17.97% | 10.34% | |||
| Income Before Tax | -1.26% | -18.64% | |||
| Income Tax Expenses | -- | -659.26% | |||
| Earnings from Continuing Operations | -1.70% | -18.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.70% | -18.21% | |||
| EBIT | 17.97% | 10.34% | |||
| EBITDA | 17.97% | 10.40% | |||
| EPS Basic | -1.13% | -17.96% | |||
| Normalized Basic EPS | 47.82% | -78.94% | |||
| EPS Diluted | -1.13% | -17.96% | |||
| Normalized Diluted EPS | 47.82% | -78.94% | |||
| Average Basic Shares Outstanding | 0.57% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.57% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||